Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods


Por: Smith, A, Armstrong, AW, Elewski, B, Rich, P, Augustin, M, Carrascosa, JM, Vender, R, Lambert, J, Pinto, JML, Hoepken, B, Kavanagh, S and Puig, L

Publicada: 1 jun 2025
Resumen:


Filiaciones:
Smith, A:
 St Vincents Hosp, Greystanes, NSW, Australia

Armstrong, AW:
 Keck Sch Med USC, Dermatol, Los Angeles, CA USA

Elewski, B:
 Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH USA

Rich, P:
 Icahn Sch Med Mt Sinai, New York, NY USA

Augustin, M:
 Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

Vender, R:
 Dermatrials Res Inc, Hamilton, ON, Canada

Lambert, J:
 UCB Pharma, Colombes, France

Pinto, JML:
 UCB Pharma, Madrid, Spain

Hoepken, B:
 UCB Pharma, Monheim, Germany

Kavanagh, S:
 UCB, Morrisville, NC USA

Puig, L:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain
ISSN: 00048380





Australasian Journal of Dermatology
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 66 Número:
Páginas:
WOS Id: 001506991900032

MÉTRICAS